VXRT
Vaxart, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.49
−2.78%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.31
- Revenue estimate
- $14.6M
Latest reported
- Last report date
- Aug 7, 2026
- EPS actual
- -$0.06
- EPS estimate
- -$0.12
- Revenue actual
- $27.2M
- Revenue estimate
- $26.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +122.9%
- Revenue beats (12Q)
- 6
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 7, 2026 | -$0.12 | -$0.06 | Beat 50.00% | $27.2M |
| May 8, 2026 | $0.02 | $0.02 | In line | $39.2M |
| Mar 12, 2026 | -$0.08 | $0.24 | Beat 398.75% | $104.2M |
| Nov 13, 2025 | -$0.07 | -$0.04 | Beat 42.86% | $72.4M |
| Aug 13, 2025 | -$0.09 | -$0.07 | Beat 22.22% | $39.7M |
| Mar 20, 2025 | -$0.10 | -$0.05 | Beat 50.00% | $15.2M |
| Nov 13, 2024 | -$0.10 | -$0.06 | Beat 40.00% | $4.9M |
| Aug 8, 2024 | -$0.03 | -$0.09 | Miss -237.46% | — |
| Mar 14, 2024 | -$0.15 | -$0.12 | Beat 20.00% | $3.2M |
| Nov 2, 2023 | -$0.18 | -$0.11 | Beat 38.89% | $446.0K |
| Aug 3, 2023 | -$0.19 | -$0.16 | Beat 15.79% | $1.4M |
| May 4, 2023 | -$0.19 | -$0.19 | In line | $675.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026